Therapeutic oligonucleotides: The road not taken

Cy A. Stein; Sanjay Goel

doi:10.1158/1078-0432.CCR-11-2013

Therapeutic oligonucleotides: The road not taken

Cy A. Stein, Sanjay Goel

Medicine

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Antisense oligonucleotide therapeutics have been in development for almost 25 years without a single U.S. Food and Drug Administration-approved product in cancer. The reasons for this absence stem, in part, from a deep lack of understanding about how to deliver these molecules to cancer cells in vivo.

Original language	English (US)
Pages (from-to)	6369-6372
Number of pages	4
Journal	Clinical Cancer Research
Volume	17
Issue number	20
DOIs	https://doi.org/10.1158/1078-0432.CCR-11-2013
State	Published - Oct 15 2011

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/1078-0432.CCR-11-2013

Cite this

@article{7b8746d7ee79479fb39dfa6930ffd37b,

title = "Therapeutic oligonucleotides: The road not taken",

abstract = "Antisense oligonucleotide therapeutics have been in development for almost 25 years without a single U.S. Food and Drug Administration-approved product in cancer. The reasons for this absence stem, in part, from a deep lack of understanding about how to deliver these molecules to cancer cells in vivo.",

author = "Stein, {Cy A.} and Sanjay Goel",

year = "2011",

month = oct,

day = "15",

doi = "10.1158/1078-0432.CCR-11-2013",

language = "English (US)",

volume = "17",

pages = "6369--6372",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "20",

}

TY - JOUR

T1 - Therapeutic oligonucleotides

T2 - The road not taken

AU - Stein, Cy A.

AU - Goel, Sanjay

PY - 2011/10/15

Y1 - 2011/10/15

N2 - Antisense oligonucleotide therapeutics have been in development for almost 25 years without a single U.S. Food and Drug Administration-approved product in cancer. The reasons for this absence stem, in part, from a deep lack of understanding about how to deliver these molecules to cancer cells in vivo.

AB - Antisense oligonucleotide therapeutics have been in development for almost 25 years without a single U.S. Food and Drug Administration-approved product in cancer. The reasons for this absence stem, in part, from a deep lack of understanding about how to deliver these molecules to cancer cells in vivo.

UR - http://www.scopus.com/inward/record.url?scp=80054094688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054094688&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-11-2013

DO - 10.1158/1078-0432.CCR-11-2013

M3 - Article

C2 - 21862637

AN - SCOPUS:80054094688

SN - 1078-0432

VL - 17

SP - 6369

EP - 6372

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 20

ER -

Therapeutic oligonucleotides: The road not taken

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this